Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SPRY

ARS Pharmaceuticals Inc

Dec 01 • 04:00PM ET

4.95

Dollar change +0.12
Percentage change 2.48	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.43	Insider Own	57.39%	Shs Outstand	93.94M	Perf Week	3.99%
Market Cap	475.20M	Forward P/E	-	EPS next Y	-0.72	Insider Trans	15.12%	Shs Float	40.91M	Perf Month	39.04%
Income	-85.38M	PEG	-	EPS next Q	-0.13	Inst Own	43.13%	Short Float / Ratio	14.51% / 4.23	Perf Quarter	-30.38%
Sales	0.00M	P/S	-	EPS this Y	29.89%	Inst Trans	15.93%	Short Interest	5.94M	Perf Half Y	-31.63%
Book/sh	2.48	P/B	2.00	EPS next Y	-17.49%	ROA	-27.38%	Target Price	8.00	Perf Year	-18.05%
Cash/sh	2.52	P/C	1.96	EPS next 5Y	-	ROE	-28.50%	52W Range	2.55 - 9.65	Perf YTD	-41.97%
Dividend	-	P/FCF	-	EPS past 5Y	-13.04%	ROI	-35.97%	52W High	-48.70%	Beta	0.53
Dividend %	-	Quick Ratio	21.87	Sales past 5Y	-19.02%	Gross Margin	-	52W Low	94.12%	ATR	0.24
Employees	20	Current Ratio	21.87	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	69.86	Volatility	3.95% 6.12%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	71.89%	Profit Margin	-	Rel Volume	0.31	Prev Close	4.83
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 09 AMC	Payout	-	Avg Volume	1.40M	Price	4.95
Recom	2.33	SMA20	15.92%	SMA50	25.72%	SMA200	-21.49%	Volume	435,477	Change	2.48%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-20-23	Downgrade	William Blair	Outperform → Mkt Perform
Jan-31-23	Initiated	Wedbush	Outperform	$10
Jan-03-23	Initiated	William Blair	Outperform	$17
Dec-13-22	Initiated	SVB Leerink	Outperform	$14

Nov-09-23 04:00PM	ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
11:02AM	ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis (GlobeNewswire)
Oct-06-23 09:03AM	ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy (epinephrine nasal spray) (GlobeNewswire) +7.02%
Oct-03-23 09:03AM	Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology (GlobeNewswire)
03:01AM	Chief Legal Officer Alexander Fitzpatrick Buys 86,258 Shares of ARS Pharmaceuticals Inc (GuruFocus.com)
07:50PM	Loading…
Sep-29-23 07:50PM	ARS Pharmaceuticals, Harmonic, and More Stocks See Action From Activist Investors (Barrons.com)
01:39PM	Hedge Fund and Insider Trading News: Dan Loeb, Crispin Odey, Ray Dalio, D. E. Shaw, Eisler Capital, Glazer Capital, Gatos Silver Inc (GATO), ARS Pharmaceuticals Inc (SPRY), and More (Insider Monkey)
10:00AM	Small Biotech Stocks Haven't Shined of Late, but I Think These 3 Could Be Stars (TheStreet.com)
10:00AM	3 Small Biotech Stocks That Could Be Stars (TheStreet.com)
Sep-21-23 12:28PM	ARS Pharmaceuticals (SPRY) Down on CRL for Nasal Spray (Zacks) +25.68%
10:43AM	Biotech Stock Roundup: GSK's Drug Approval, MRNA's Vaccine News, PTCT & SPRY Down (Zacks)
06:28AM	Feds Message Is Louder Than Its Rate Call. Why Thats Critical for Investors. (Barrons.com)
Sep-20-23 12:42PM	Why Shares of ARS Pharmaceuticals Are Plummeting on Wednesday (Motley Fool) -55.79%
10:31AM	FDA says it needs more research before deciding to approve nasal spray to treat dangerous allergies (AP Finance)
10:26AM	FDAs Surprise Rejection of No-Shot Alternative to EpiPen Halves Shares of ARS Pharma (Barrons.com)
09:49AM	Loading…
09:49AM	FDA Declines to Approve Epinephrine Nasal Spray, Asks for Additional Data (The Wall Street Journal)
06:13AM	ARS Pharma shares plummet after FDA asks for extra test of nasal spray (Investing.com)
Sep-19-23 10:49PM	FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Study (GlobeNewswire) -11.22%
Sep-08-23 07:10PM	Imperial Petroleum, ARS Pharmaceuticals Stock, and More See Action From Activist Investors (Barrons.com)
Aug-10-23 04:00PM	ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Jun-20-23 08:00AM	ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis (GlobeNewswire)
May-15-23 02:11PM	ARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal Spray (Zacks)
09:00AM	ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-12-23 11:51AM	Why ARS Pharmaceuticals Stock Is Soaring Today (Benzinga) +77.88%
May-11-23 07:01PM	FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis (GlobeNewswire)
May-09-23 09:10AM	ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis (GlobeNewswire) -14.31%
Apr-21-23 10:05AM	Companies Like ARS Pharmaceuticals (NASDAQ:SPRY) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-28-23 09:39AM	ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis (GlobeNewswire)
Mar-25-23 09:10AM	ARS Pharmaceuticals Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Mar-23-23 04:01PM	ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
06:19AM	Loading…
Mar-22-23 06:19AM	One ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider upped their stake in the previous year (Simply Wall St.) -5.56%
Feb-23-23 04:01PM	ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors (GlobeNewswire)
Feb-22-23 04:05PM	ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis (GlobeNewswire)
Feb-09-23 06:30AM	ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023 (GlobeNewswire) +5.76%
05:43AM	Insiders own 34% of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) shares but individual investors control 36% of the company (Simply Wall St.)
Nov-10-22 08:00AM	ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis (GlobeNewswire)

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fitzpatrick Alexander A	Chief Legal Officer	Sep 29	Buy	3.78	46,258	174,994	89,227	Oct 02 04:23 PM
Fitzpatrick Alexander A	Chief Legal Officer	Sep 28	Buy	3.62	40,000	144,960	42,969	Oct 02 04:23 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Sep 21	Buy	3.03	2,700,000	8,183,526	8,556,774	Sep 25 04:30 PM
Shawver Laura	Director	Sep 01	Option Exercise	1.27	100,000	127,000	310,346	Sep 05 08:04 PM
Shawver Laura	Director	Sep 01	Sale	7.71	100,000	770,520	210,346	Sep 05 08:04 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Aug 29	Buy	6.20	3,750,000	23,250,000	5,856,774	Aug 31 05:26 PM
ORBIMED ADVISORS LLC	Director	Aug 29	Buy	6.20	500,000	3,100,000	8,019,187	Aug 31 05:26 PM
Thompson Peter A.	Director	Aug 29	Buy	6.20	500,000	3,100,000	8,019,187	Aug 31 05:18 PM
Shawver Laura	Director	Aug 04	Option Exercise	1.27	18,897	23,999	229,243	Aug 07 05:05 PM
Shawver Laura	Director	Aug 04	Sale	7.06	18,897	133,471	210,346	Aug 07 05:05 PM
Shawver Laura	Director	Aug 03	Option Exercise	1.27	26,107	33,156	236,453	Aug 07 05:05 PM
Shawver Laura	Director	Aug 03	Sale	7.01	26,107	183,018	210,346	Aug 07 05:05 PM
Shawver Laura	Director	Aug 02	Option Exercise	1.27	36,281	46,077	246,627	Aug 03 06:03 PM
Shawver Laura	Director	Aug 02	Sale	7.09	36,281	257,265	210,346	Aug 03 06:03 PM
Shawver Laura	Director	Aug 01	Option Exercise	1.27	18,715	23,768	229,061	Aug 03 06:03 PM
Shawver Laura	Director	Aug 01	Sale	7.19	18,715	134,576	210,346	Aug 03 06:03 PM
Shawver Laura	Director	Jul 07	Option Exercise	1.27	8,858	11,250	219,204	Jul 07 08:16 PM
Shawver Laura	Director	Jul 07	Sale	6.36	8,858	56,372	210,346	Jul 07 08:16 PM
Shawver Laura	Director	Jul 06	Option Exercise	1.27	33,510	42,558	243,856	Jul 06 08:55 PM
Shawver Laura	Director	Jul 06	Sale	6.34	33,510	212,554	210,346	Jul 06 08:55 PM
Shawver Laura	Director	Jul 05	Option Exercise	1.27	31,112	39,512	241,458	Jul 06 08:55 PM
Shawver Laura	Director	Jul 05	Sale	6.41	31,112	199,552	210,346	Jul 06 08:55 PM
Shawver Laura	Director	Jul 03	Option Exercise	1.27	26,520	33,680	236,866	Jul 06 08:55 PM
Shawver Laura	Director	Jul 03	Sale	6.72	26,520	178,347	210,346	Jul 06 08:55 PM
Shawver Laura	Director	Jun 02	Option Exercise	1.27	26,941	34,215	237,287	Jun 02 07:48 PM
Shawver Laura	Director	Jun 02	Sale	6.95	26,941	187,240	210,346	Jun 02 07:48 PM
Shawver Laura	Director	Jun 01	Option Exercise	1.27	73,059	92,785	283,405	Jun 02 07:48 PM
Shawver Laura	Director	Jun 01	Sale	6.80	73,059	496,801	210,346	Jun 02 07:48 PM
Shawver Laura	Director	May 09	Option Exercise	1.27	42,900	54,483	253,246	May 10 04:53 PM
Shawver Laura	Director	May 09	Sale	5.31	42,900	227,799	210,346	May 10 04:53 PM
Shawver Laura	Director	May 08	Option Exercise	1.27	57,100	72,517	267,446	May 10 04:53 PM
Shawver Laura	Director	May 08	Sale	6.16	57,100	351,736	210,346	May 10 04:53 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SPRY

ARS Pharmaceuticals Inc

Upgrade your FINVIZ experience